BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/11/2024 10:43:38 AM | Browse: 242 | Download: 872
 |
Received |
|
2024-08-19 08:20 |
|
Peer-Review Started |
|
2024-06-17 12:35 |
|
First Decision by Editorial Office Director |
|
2024-10-13 14:05 |
|
Return for Revision |
|
2024-10-14 00:00 |
|
Revised |
|
2024-10-21 15:14 |
|
Publication Fee Transferred |
|
2024-10-24 02:03 |
|
Second Decision by Editor |
|
2024-11-25 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-25 07:01 |
|
Articles in Press |
|
2024-11-25 07:01 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-29 09:23 |
|
Publish the Manuscript Online |
|
2024-12-11 10:19 |
| ISSN |
2218-4333 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi-Qiong Zhou, Peng Wan, Seng Zhang, Yuan Ren, Hong-Tao Li and Qing-Hua Ke |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qing-Hua Ke, Chief Physician, PhD, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, No. 40 Jinglong Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com |
| Key Words |
Immunotherapy; Programmed cell death 1 inhibitor; Sintilimab; Chemotherapy; Metastatic; Pancreatic ductal adenocarcinoma |
| Core Tip |
This study aimed to explore the feasibility and effectiveness of combining the programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine (combination group) vs using S-1 and gemcitabine alone (chemotherapy group) for treating liver metastatic pancreatic adenocarcinoma. The combination of programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine demonstrated effectiveness and safety for treating liver metastatic pancreatic ductal adenocarcinoma, meriting further investigation. |
| Publish Date |
2024-12-11 10:19 |
| Citation |
Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma. World J Clin Oncol 2025; 16(2): 98079 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i2/98079.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i2.98079 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
